Sight Sciences, Inc. (SGHT)
|Net Income (ttm)||-37.76M|
|Trading Day||July 27|
|Day's Range||34.22 - 36.71|
|52-Week Range||27.13 - 38.25|
Sight Sciences Announces Multiple Presentations at the 2021 American Society of Cataract and Refractive Surgery Annua...
New safety and efficacy data from both retrospective and prospective studies of the OMNI Surgical System and a prospective study of the TearCare System to be presented New safety and efficacy data from ...
Sight Sciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase...
MENLO PARK, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devices that target the ...
MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devises that target the ...
Sight Sciences, Inc. has filed to go public with an IPO on the NASDAQ.
Sight Sciences' mission is to transform ophthalmology and optometry through the development and commercialization of proprietary devices that target the underlying causes of the world’s most prevalent eye diseases. Sight Sciences is passionate about improving patients’ lives. Our currently marketed products, the OMNI Surgical System, or OMNI, and the TearCare System, or TearCare, target two of the world’s most prevalent and underserved eye diseases, glaucoma and dry eye disease, or DED, respectively. OMNI is a handheld, single-use, therap... [Read more...]
|IPO Date |
Jul 15, 2021
|Stock Exchange |
|Ticker Symbol |
In 2020, Sight Sciences's revenue was $27.64 million, an increase of 18.38% compared to the previous year's $23.35 million. Losses were -$34.69 million, 34.1% more than in 2019.